Research programme: metabolic disorders therapeutics - Xenon
Alternative Names: Metabolic disorders therapy research programme - Xenon; Metabolic syndrome therapy research programme - Xenon; Obesity therapy research programme - Xenon; Research programme: metabolic syndrome therapy - Xenon; Research programme: obesity therapy - Xenon; XEN-103Latest Information Update: 04 Nov 2017
At a glance
- Originator Xenon Pharmaceuticals
- Class Small molecules
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic syndrome; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-syndrome in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Canada
- 02 Jun 2010 Preclinical development is ongoing in Canada